1. Data & Insights

The $700 Copay That Changed Everything

Today’s guest post comes from Stephen Hom, EVP, Chief Commercial Officer, and Co-Founder of RIS Rx.

Stephen argues that patient affordability remains one of the most critical—and often overlooked—barriers to treatment adherence. Drawing on his experience as a community pharmacist, he suggests that cost isn’t just a financial issue—it’s a clinical one.

To learn about RIS Rx’s Benefit Patient Solution (BPS) and other tools, request your savings snapshot.

Read on for Stephen’s insights.

Read more »

       
View Original Article
https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!